サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1777774

動物用鎮静剤の世界市場

Animal Sedatives

出版日
ページ情報
英文 364 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
動物用鎮静剤の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 364 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

動物用鎮静剤の世界市場は2030年までに4億8,130万米ドルに達する見込み

2024年に3億7,190万米ドルと推定される動物用鎮静剤の世界市場は、2030年には4億8,130万米ドルに達し、分析期間2024-2030年のCAGRは4.4%で成長すると予測されます。本レポートで分析したセグメントの1つであるα2アドレナリン受容体作動薬は、CAGR 5.1%を記録し、分析期間終了時には2億1,280万米ドルに達すると予測されます。ベンゾジアゼピン系薬剤セグメントの成長率は、分析期間中CAGR 4.2%と推定されます。

米国市場は1億130万米ドルと推定、中国はCAGR 8.1％で成長予測

米国の動物用鎮静剤市場は、2024年に1億130万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.1%として、2030年には予測市場規模9,980万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.8％と3.5％と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

世界の動物用鎮静剤市場- 主要動向と促進要因まとめ

動物用鎮静剤市場は、獣医学、家畜管理、野生動物保護など、安全で効果的な麻酔ソリューションへのニーズの高まりにより、近年大きく拡大しています。これらの鎮静剤は、外科処置、疼痛管理、行動制御、動物の輸送など様々な目的で使用されています。動物医療が進歩し続けるにつれ、精密な麻酔薬への需要が高まり、獣医師が動物へのリスクを最小限に抑えながら複雑な処置を行えるようになっています。

動物用鎮静剤市場を形成する大きな動向の一つは、副作用を最小限に抑えながらバランスの取れた鎮静効果を得るために複数の薬剤を併用する多剤併用麻酔技術へのシフトです。このアプローチは、医療介入中の家畜および外来種の安全を確保するために特に重要となっています。さらに、ペット数の増加と動物ヘルスケアへの支出の増加が動物用医薬品産業の拡大に寄与しており、安全性プロファイルを改善した、より新しく効率的な鎮静剤の開発につながっています。さらに、動物研究や実験室での試験の増加も、特殊な麻酔化合物に対する需要を押し上げており、鎮静は獣医学や生物医学の応用に不可欠な要素となっています。

動物用麻酔における技術革新は、動物用鎮静剤をどのように向上させているか？

動物用麻酔の分野では目覚ましい技術革新が見られ、動物用鎮静剤の処方、投与、モニタリングの方法が変化しています。最も重要な進歩のひとつは、短時間で回復し、動物へのストレスを軽減できる短時間作用型で可逆性の鎮静剤の開発です。従来の鎮静剤は、眠気が長引いたり、生理学的合併症を引き起こしたりすることが多かったが、α2アドレナリン作動薬や解離性麻酔薬を含む最新の製剤は、心臓血管の安定性を維持しながら、鎮静の速やかな発現とコントロールが可能です。

もう一つの画期的な技術革新は、動物の鎮静のために吸入麻酔を使用するようになってきたことです。イソフルランやセボフルランなどのガス麻酔薬は、その正確な投与量制御、迅速な導入、容易な可逆性により、好ましい選択肢となっています。これらの吸入麻酔薬は、安定した麻酔深度を維持することが重要な複雑な外科手術において特に有用です。さらに、リアルタイム・モニタリング・センサーを備えた自動麻酔デリバリー・システムの採用は、動物の生理学的パラメーターに基づいて薬物投与を最適化することにより、獣医診療の精度を高めています。

さらに、野生動物鎮静用のダーティング機構などの遠隔ドラッグデリバリーシステムの進歩は、大型で攻撃的な動物の治療や移動のための麻酔方法に革命をもたらしています。これらの技術は、正確な投与量を確保しながら動物へのストレスを最小限に抑え、野生動物の保護活動において貴重なツールとなっています。AI主導の鎮静モニタリングツールの統合もまた、ゲームチェンジャーとして台頭しており、獣医師が鎮静の深さ、バイタルサイン、回復パターンをリアルタイムで追跡できるようにすることで、麻酔管理の安全性と有効性を向上させています。

動物用鎮静剤業界を形成する新たな市場動向とは？

動物用鎮静剤市場は、規制政策、獣医学の専門性の高まり、動物福祉イニシアチブの拡大により、大きな変革期を迎えています。主な動向の一つは、麻酔薬、特に動物用鎮静剤によく使用されるオピオイドやベンゾジアゼピンに対する規制当局の監視が強まっていることです。政府や規制機関は、薬物の誤用や環境への影響に対する懸念から、鎮静剤の流通や使用に対する規制を強化しています。このため、乱用の可能性が低く、より安全な代謝プロファイルを持つ代替鎮静剤の研究開発への投資が増加しています。

もうひとつの大きな動向は、動物種に特化した麻酔が重視されるようになってきたことです。標準化された鎮静プロトコールが存在する人間医療とは異なり、獣医麻酔はコンパニオンペットや家畜からエキゾチックで絶滅の危機に瀕した野生動物まで、多様な動物種に対応しなければならないです。このため、特定の生理学的・代謝的ニーズに合わせて設計された標的鎮静製剤が開発され、最適な効果と合併症の減少が保証されています。さらに、個別化された獣医学的治療の動向は、動物の体重、年齢、病歴に基づいて投与量を調整し、鎮静処置の安全性と結果を改善する、鎮静剤の処方方法に影響を及ぼしています。

遠隔医療や遠隔獣医療相談の普及も、動物用鎮静剤市場に影響を与えています。獣医師は現在、鎮静プロトコルを推奨する前に動物を評価するため、特にペットの軽微な処置や不安管理にデジタルプラットフォームを使用しています。これはさらに、注射を必要とせずに穏やかな鎮静効果をもたらす鎮静剤入りの経口・経皮製剤の台頭によって補完され、在宅での動物ケアや旅行関連の不安管理に理想的なものとなっています。このような新たな動向は、動物用鎮静法の範囲を広げるだけでなく、動物ヘルスケアにおける安全性、効率性、利用しやすさの新たな基準を設定しつつあります。

動物用鎮静剤市場の成長の原動力は？

動物用鎮静剤市場の成長は、獣医薬理学の進歩、ペット医療サービスに対する需要の増加、精密畜産の拡大など、いくつかの要因によって牽引されています。主な成長要因のひとつは、コンパニオンアニマルの飼育数の急増であり、ペットの飼い主は、鎮静支援手術、歯科処置、行動管理など、動物に対する高度医療をますます求めるようになっています。ペットの福祉に対する意識の高まりと専門的な獣医療へのアクセスが、猫、犬、ウサギなどの小動物用に調整された高品質の鎮静剤の採用に拍車をかけています。

もう一つの重要な推進力は、家畜や馬の管理方法の拡大です。大規模な酪農、養鶏、食肉生産施設では、去勢、除角、削蹄などの日常的な医療処置を容易にする一方で、ストレスによる傷害を最小限に抑えるために鎮静剤を採用しています。食肉品質の向上と食品生産における倫理的な動物取扱いの確保にますます焦点が当てられていることが、農業分野における安全で効果的な鎮静剤の選択肢に対する需要をさらに高めています。さらに、動物用製薬会社の世界の成長と研究開発への投資の増加は、薬物動態を改善し副作用を最小限に抑えた次世代の動物用鎮静剤の開発を加速させています。

野生動物の保護・救助活動に対するニーズの高まりも、市場拡大に極めて重要な役割を果たしています。気候変動や生息地の破壊によって人間と野生動物との相互作用が増大する中、保護活動家や野生動物の獣医師は、動物の移動、リハビリテーション、緊急医療に高度な鎮静製剤を利用するようになっています。さらに、特に新興市場では、動物用ヘルスケア・インフラの改善を目的とした政府の取り組みが、鎮静剤メーカーに製品ラインナップを拡大する有利な機会をもたらしています。鎮静技術の絶え間ない進歩と進化する獣医診療により、世界の動物用鎮静剤市場は持続的な成長を遂げ、動物ヘルスケアと福祉の基準を再定義する態勢が整っています。

セグメント

薬剤クラス（α2アドレナリン受容体作動薬、ベンゾジアゼピン系薬剤、フェノチアジン系薬剤、その他薬剤クラス別）;投与経路（非経口経路、経口経路）;エンドユーザー（病院エンドユーザー、専門センターエンドユーザー）

調査対象企業の例

  • Bimeda Inc.
  • Ceva Animal Health, LLC
  • Chanelle Pharma
  • Dechra Veterinary Products
  • Hikma Pharmaceuticals PLC
  • Orion Corporation
  • Ouro Fino Saude Animal Group
  • Randlab Australia Pty Ltd
  • vetcare. fi.
  • Vetoquinol
  • Virbac Corporation
  • Zoetis Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29161

Global Animal Sedatives Market to Reach US$481.3 Million by 2030

The global market for Animal Sedatives estimated at US$371.9 Million in the year 2024, is expected to reach US$481.3 Million by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Alpha-2 Adrenergic Receptor Agonists, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$212.8 Million by the end of the analysis period. Growth in the Benzodiazepines segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$101.3 Million While China is Forecast to Grow at 8.1% CAGR

The Animal Sedatives market in the U.S. is estimated at US$101.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$99.8 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Animal Sedatives Market - Key Trends & Drivers Summarized

The animal sedatives market has been expanding significantly in recent years, driven by the increasing need for safe and effective anesthetic solutions across veterinary medicine, livestock management, and wildlife conservation. These sedatives are used for various purposes, including surgical procedures, pain management, behavioral control, and transportation of animals. As veterinary healthcare continues to advance, the demand for precision anesthetic drugs has risen, enabling veterinarians to perform complex procedures with minimal risk to the animals.

One of the major trends shaping the animal sedatives market is the shift toward multimodal anesthesia techniques, which involve the combination of multiple drugs to achieve a balanced sedative effect while minimizing side effects. This approach has become particularly crucial for ensuring the safety of both domesticated animals and exotic species during medical interventions. Additionally, the growing pet population and increased spending on animal healthcare are contributing to the expansion of the veterinary pharmaceutical industry, leading to the development of newer, more efficient sedatives with improved safety profiles. Furthermore, the rise in animal research and laboratory testing is also boosting the demand for specialized anesthetic compounds, making sedation an integral part of veterinary and biomedical applications.

How Are Innovations in Veterinary Anesthesia Enhancing Animal Sedatives?

The field of veterinary anesthesia has witnessed remarkable innovations, transforming how animal sedatives are formulated, administered, and monitored. One of the most significant advancements is the development of short-acting and reversible sedatives, which allow for quicker recovery times and reduced stress on the animal. Traditional sedatives often led to prolonged drowsiness and physiological complications, but modern formulations, including alpha-2 adrenergic agonists and dissociative anesthetics, provide rapid onset and controlled sedation while maintaining cardiovascular stability.

Another groundbreaking innovation is the increasing use of inhalant anesthesia for animal sedation. Gaseous anesthetics such as isoflurane and sevoflurane have become preferred choices due to their precise dosage control, rapid induction, and easy reversibility. These inhalants are particularly useful in complex surgical procedures where maintaining a steady depth of anesthesia is critical. Furthermore, the adoption of automated anesthesia delivery systems, equipped with real-time monitoring sensors, is enhancing precision in veterinary practices by optimizing drug administration based on the animal’s physiological parameters.

Additionally, the advancement of remote drug delivery systems, such as darting mechanisms for wildlife sedation, is revolutionizing how large and aggressive animals are anesthetized for medical treatment or relocation. These technologies minimize stress on the animal while ensuring accurate dosing, making them invaluable tools in wildlife conservation efforts. The integration of AI-driven sedation monitoring tools is also emerging as a game-changer, allowing veterinarians to track sedation depth, vital signs, and recovery patterns in real time, thereby improving safety and efficacy in anesthesia management.

What Are the Emerging Market Trends Shaping the Animal Sedatives Industry?

The animal sedatives market is undergoing significant transformations driven by regulatory policies, growing veterinary specialization, and the expansion of animal welfare initiatives. One of the key trends is the rising regulatory scrutiny on anesthetic drugs, particularly opioids and benzodiazepines, which are commonly used in veterinary sedation. Governments and regulatory bodies are tightening controls on sedative distribution and usage due to concerns over drug misuse and environmental impact. This has led to increased investment in the research and development of alternative sedatives with lower abuse potential and safer metabolic profiles.

Another major trend is the growing emphasis on species-specific anesthesia. Unlike human medicine, where standardized sedative protocols exist, veterinary anesthesia must cater to a diverse range of animal species, from companion pets and livestock to exotic and endangered wildlife. This has led to the development of targeted sedative formulations designed for specific physiological and metabolic needs, ensuring optimal efficacy and reduced complications. Additionally, the trend of personalized veterinary care is influencing the way sedatives are prescribed, with tailored dosages based on an animal’s weight, age, and medical history, improving safety and outcomes in sedation procedures.

The increasing adoption of telemedicine and remote veterinary consultations is also impacting the animal sedatives market. Veterinarians are now using digital platforms to assess animals before recommending sedation protocols, especially for minor procedures and anxiety management in pets. This is further complemented by the rise of sedative-infused oral and transdermal formulations, which provide mild sedation without requiring injections, making them ideal for home-based animal care and travel-related anxiety management. These emerging trends are not only broadening the scope of veterinary sedation but are also setting new benchmarks for safety, efficiency, and accessibility in animal healthcare.

What Is Driving the Growth of the Animal Sedatives Market?

The growth in the animal sedatives market is driven by several factors, including advancements in veterinary pharmacology, increasing demand for pet healthcare services, and the expansion of precision livestock farming. One of the major growth drivers is the surge in companion animal ownership, with pet owners increasingly seeking advanced medical treatments for their animals, including sedation-assisted surgeries, dental procedures, and behavioral management. The rising awareness of pet welfare and access to specialized veterinary care are fueling the adoption of high-quality sedatives tailored for small animals such as cats, dogs, and rabbits.

Another key driver is the expansion of livestock and equine management practices. Large-scale dairy, poultry, and meat production facilities are adopting sedatives to facilitate routine medical procedures such as castration, dehorning, and hoof trimming while minimizing stress-induced injuries. The increasing focus on improving meat quality and ensuring ethical animal handling in food production is further contributing to the demand for safe and effective sedative options in the agricultural sector. Additionally, the global growth of veterinary pharmaceutical companies and increased investments in R&D are accelerating the development of next-generation animal sedatives with improved pharmacokinetics and minimal side effects.

The growing need for wildlife conservation and rescue operations is also playing a pivotal role in market expansion. With climate change and habitat destruction leading to increased human-wildlife interactions, conservationists and wildlife veterinarians are increasingly relying on advanced sedative formulations for animal relocation, rehabilitation, and emergency medical care. Furthermore, government initiatives aimed at improving veterinary healthcare infrastructure, particularly in emerging markets, are providing lucrative opportunities for sedative manufacturers to expand their product offerings. With continuous advancements in sedation technology and evolving veterinary practices, the global animal sedatives market is poised for sustained growth, redefining the standards of animal healthcare and welfare.

SCOPE OF STUDY:

The report analyzes the Animal Sedatives market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines, Other Drug Classes); Administration Route (Parenteral Route, Oral Route); End-Use (Hospitals End-Use, Specialty Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Bimeda Inc.
  • Ceva Animal Health, LLC
  • Chanelle Pharma
  • Dechra Veterinary Products
  • Hikma Pharmaceuticals PLC
  • Orion Corporation
  • Ouro Fino Saude Animal Group
  • Randlab Australia Pty Ltd
  • vetcare. fi.
  • Vetoquinol
  • Virbac Corporation
  • Zoetis Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Animal Sedatives - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Veterinary Care Drives Market Growth for Safe and Effective Animal Sedatives
    • Rising Awareness About Pet Anxiety and Stress Management Encourages the Use of Sedatives for Companion Animals
    • Expansion of Livestock Farming and Meat Processing Industries Spurs Demand for Pre-Slaughter Sedation Solutions
    • Technological Advancements in Anesthetic Formulations Improve Safety and Efficacy of Animal Sedatives
    • Increasing Number of Veterinary Surgeries and Procedures Strengthens the Business Case for Sedation Products
    • Stringent Regulatory Guidelines for Animal Welfare Encourage the Use of Humane Sedation Practices
    • Growing Pet Adoption Rates and Increasing Veterinary Visits Expand Market Opportunities for Companion Animal Sedatives
    • Rising Awareness About the Importance of Stress-Free Transportation Drives Demand for Animal Sedatives
    • Emergence of Natural and Herbal-Based Sedatives to Meet Consumer Preference for Organic Solutions
    • Increasing Concerns Over Anesthetic Side Effects Drive Innovation in Safer and Targeted Sedation Drugs
    • Expanding Research into Species-Specific Sedative Requirements Encourages Tailored Product Development
    • Growth of Exotic Pet Ownership Spurs Demand for Specialized Sedation Solutions
    • Rising Veterinary Training Programs and Education Enhance Proper Sedative Use and Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Animal Sedatives Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Animal Sedatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Animal Sedatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Animal Sedatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Alpha-2 Adrenergic Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Alpha-2 Adrenergic Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Alpha-2 Adrenergic Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Benzodiazepines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Benzodiazepines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Benzodiazepines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Phenothiazines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Phenothiazines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Phenothiazines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Specialty Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Animal Sedatives by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Animal Sedatives by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Animal Sedatives by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Animal Sedatives by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Animal Sedatives by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Animal Sedatives by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Animal Sedatives by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Animal Sedatives by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Animal Sedatives by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Animal Sedatives by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Animal Sedatives by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Animal Sedatives by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • Animal Sedatives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Animal Sedatives by Drug Class - Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Animal Sedatives by Drug Class - Percentage Breakdown of Value Sales for Alpha-2 Adrenergic Receptor Agonists, Benzodiazepines, Phenothiazines and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Animal Sedatives by Administration Route - Parenteral Route and Oral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Animal Sedatives by Administration Route - Parenteral Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Animal Sedatives by Administration Route - Percentage Breakdown of Value Sales for Parenteral Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Animal Sedatives by End-Use - Hospitals End-Use and Specialty Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Animal Sedatives by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Specialty Centers End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION